Latest Administration News

Multistack International has announced the discontinuation of its current business operations following a significant asset sale that settled a $3.55 million loan, signaling a major strategic shift for the company.

Multistack International Limited reported a net cash outflow for the quarter ending June 2025 but has strengthened its balance sheet through major loan repayments and is progressing acquisition discussions with SuperLink.

Cycliq Group Ltd reported a 7% increase in customer receipts to $4.8 million for FY2025, alongside a positive net operating cash inflow, driven by strong Q4 sales and new digital initiatives.

Openn Negotiation Ltd has successfully exited voluntary administration following creditor approval of a recapitalisation plan, supported by an interest-free loan from its major shareholder. Despite no substantive business activity this quarter, the company now has over two quarters of funding runway.

Nelson Resources reports promising high-grade gold assay results from rock chip samples at its Yarri tenements, revealing new exploration targets and confirming mineralisation beyond known zones.

Neurizon Therapeutics has formally responded to the FDA's clinical hold on its lead ALS drug NUZ-001, submitting new animal safety data. The company aims to join the HEALEY ALS Platform Trial by late 2025, pending regulatory approval.

Paterson Resources has secured heritage clearance and reported promising metallurgical results at its Grace Gold-Copper Project, setting the stage for a significant drilling campaign to upgrade its resource estimate.

Peako Limited halted field exploration in the June quarter due to seasonal and logistical challenges, surrendered two tenements, and announced the resignation of its CEO, while maintaining a solid cash position.

FAR Limited reports robust production from Senegal’s Sangomar field and receives a provisional $11.5 million contingent payment, while addressing a $6 million indemnity claim from Woodside Energy.

Dimerix has secured a significant licensing agreement with Amicus Therapeutics for its kidney disease drug candidate DMX-200 in the US, receiving a US$30 million upfront payment and advancing its Phase 3 trial with FDA endorsement of a key clinical endpoint.

Stockland updates its interim dividend for the six months ending June 2025, confirming an estimated payout of AUD 0.172 per security and announcing the Dividend Reinvestment Plan price at AUD 5.43 with a 1% discount.

Newmont Corporation has announced a quarterly dividend of USD 0.25 per security, payable on September 29, 2025, with a default 30% U.S. withholding tax applying to non-resident holders.